Topic Hub
Semaglutide: Independent research hub
A focused topic cluster covering Semaglutide's mechanism, STEP/SUSTAIN/SELECT trial evidence, safety profile and regulatory status. Refreshed monthly.
- Articles
- 16
- Last updated
- May 2026
- Coverage
- Mechanism · Evidence · Safety · Regulatory
Compound profile
Semaglutide
Widely-prescribed GLP-1 receptor agonist with substantial trial evidence for weight loss and type 2 diabetes.
Mechanism and biology
How Semaglutide Works: A GLP-1 Receptor Agonist Explained
Explore how semaglutide activates GLP-1 receptors to regulate appetite, glucose metabolism, and weight management at the molecular level.
Read articleSemaglutide and the GLP-1 Receptor Agonist Class
Learn how semaglutide fits within the GLP-1 receptor agonist drug class and how it compares to other members of this therapeutic category.
Read articleHow Semaglutide Drives Weight Loss: The Mechanism
Detailed examination of how semaglutide's GLP-1 receptor agonism translates into sustained weight loss through appetite suppression, metabolic adaptation, and energy balance.
Read articleTrial evidence and clinical data
The STEP Trial Program: Semaglutide for Weight Management
Comprehensive review of the STEP trial program—four landmark randomised controlled trials demonstrating semaglutide efficacy in chronic weight management.
Read articleThe SUSTAIN Trial Program: Semaglutide for Type 2 Diabetes
Overview of the SUSTAIN trial program—13 Phase 3 trials evaluating semaglutide for type 2 diabetes glycaemic control and cardiovascular outcomes.
Read articleThe SELECT Trial: Semaglutide and Cardiovascular Outcomes
In-depth review of the SELECT trial, which demonstrated cardiovascular benefits of semaglutide in obese individuals without type 2 diabetes.
Read articleSemaglutide Weight Loss Evidence: A Detailed Review
Comprehensive synthesis of clinical trial evidence demonstrating semaglutide's efficacy for weight loss across diverse populations and treatment contexts.
Read articleSemaglutide for Type 2 Diabetes: The Evidence Base
Comprehensive synthesis of semaglutide's clinical evidence for type 2 diabetes glycaemic control, cardiovascular protection, and renal outcomes.
Read articleAdverse events and safety signals
Semaglutide Side Effects: Comprehensive Research Review
In-depth analysis of semaglutide side effects from clinical trials, including incidence, severity, duration, and mechanisms of common and serious adverse events.
Read articleSemaglutide Safety Profile: A Detailed Look
Comprehensive examination of semaglutide's overall safety profile, including cardiovascular, metabolic, and systemic safety outcomes from clinical trials.
Read articleThe Semaglutide Thyroid C-Cell Boxed Warning Explained
Comprehensive explanation of the black-box thyroid C-cell carcinogenicity warning for semaglutide, its origin, clinical implications, and risk-benefit assessment.
Read articleRegulatory status and approvals
Semaglutide and the TGA: Australian Approval Status
Overview of semaglutide's regulatory status in Australia, TGA approval pathways, ARTG registration, PBS listing, and access through prescription channels.
Read articleSemaglutide Global Regulatory Status
Overview of semaglutide's regulatory approval status across major global markets, including the United States, Europe, Australia, Canada, and other regions.
Read articleClass and head-to-head comparisons
Semaglutide vs Tirzepatide: A Detailed Comparison
Comprehensive comparison of semaglutide (GLP-1 agonist) and tirzepatide (GIP/GLP-1 agonist), including mechanism, efficacy, safety, and clinical context.
Read articleOzempic vs Wegovy: Same Molecule, Different Indications
Explanation of the distinction between Ozempic and Wegovy—two brand names for the same semaglutide molecule, approved for different indications.
Read article